VIVUS Announces Date of 2018 Annual Meeting
May 04 2018 - 4:05PM
VIVUS, Inc. (Nasdaq:VVUS) (the “Company”), a biopharmaceutical
company, today announced that the Company will hold its 2018 Annual
Meeting of Stockholders (the “2018 Annual Meeting”) on September 7,
2018. Because the 2018 Annual Meeting will be held more than
30 days from the anniversary date of the 2017 Annual Meeting of
Stockholders, the Company is informing its stockholders of the
revised deadlines for proposals, director nominations and other
related matters for consideration at the 2018 Annual Meeting.
Pursuant to Rule 14a‑8 under the Securities Exchange Act of
1934, as amended (the “Exchange Act”), stockholders may present
proper proposals for inclusion in the 2018 Proxy Statement and for
consideration at the Company’s 2018 Annual Meeting. To be
eligible for inclusion in the 2018 Proxy Statement, a proposal must
be received by the Company no later than May 21, 2018 and must
otherwise comply with Rule 14a‑8.
In addition, under the Company’s Amended and Restated Bylaws, as
further amended, in order to nominate a director or bring any other
business before the stockholders at the 2018 Annual Meeting that
will not be included in the 2018 Proxy Statement, the proposal must
be received by the Company’s Corporate Secretary on or between May
10, 2018 and June 9, 2018.
All stockholder proposals, director nominations and other
related matters must comply, as applicable, with Delaware law, the
rules and regulations under the Exchange Act and the Company’s
Amended and Restated Bylaws, as further amended.
About VIVUS
VIVUS is a biopharmaceutical company committed to the
development and commercialization of innovative therapies that
focus on advancing treatments for patients with serious unmet
medical needs. For more information about the Company, please
visit www.vivus.com.
Forward-Looking Statements
Certain statements in this press release are forward-looking
within the meaning of the Private Securities Litigation Reform Act
of 1995. These statements may be identified by the use of
forward-looking words such as “anticipate,” “believe,” “forecast,”
“estimate,” “expect,” “intend,” “likely,” “may,” “plan,”
“potential,” “predict,” “opportunity” and “should,” among others.
There are a number of factors that could cause actual events to
differ materially from those indicated by such forward-looking
statements. Investors should read the risk factors set forth in
VIVUS’ Form 10-K for the year ended December 31, 2017 as filed on
March 14, 2018, and as amended by the Form 10-K/A filed on April
26, 2018, and periodic reports filed with the Securities and
Exchange Commission. VIVUS does not undertake an obligation to
update or revise any forward-looking statements.
VIVUS,
Inc.
Mark
Oki
Chief Financial
Officer
oki@vivus.com
650-934-5200
Investor Relations: Lazar PartnersDavid
CareyManaging Director
dcarey@lazarpartners.com212-867-1768
VIVUS (NASDAQ:VVUS)
Historical Stock Chart
From Sep 2024 to Oct 2024
VIVUS (NASDAQ:VVUS)
Historical Stock Chart
From Oct 2023 to Oct 2024